Cat. No. |
Product Name |
Information |
PC-63110 |
HJC-0338
|
HJC-0338 is a potent and specific EPAC2 antagonist with IC50 of 0.4 uM for competing with 8-NBD-cAMP in binding EPAC2. |
PC-63108 |
HJC 0197
|
HJC 0197 is a potent Exchange proteins directly activated by cAMP (EPAC) inhibitor with IC50 of 4.0 uM. |
PC-63106 |
NY-0173
|
NY-0173 is a potent Exchange proteins directly activated by cAMP (EPAC) inhibitor with IC50 of 4.0 uM for EPAC1.. |
PC-63104 |
NY-0123
|
NY-0123 is a novel potent Exchange proteins directly activated by cAMP (EPAC) antagonist with IC50 of 0.9 and 2.4 uM for EPAC1 and EPAC2, respectively. |
PC-62968 |
Imazapic
|
Imazapic is a herbicide that controls many broad leaf weeds and controls or suppresses some grasses in pasture.. |
PC-62967 |
Imazaquin
|
Imazaquin is an imidazolinone herbicide that effectively controls a broad spectrum of weed species, by inhibiting acetohydroxy acid synthase (AHAS).. |
PC-62928 |
Buthionine Sulfoximine
|
Buthionine Sulfoximine (BSO) is a glutathione (GSH)-depleting reagent that inhibits gamma-glutamylcysteine synthetase, the enzyme required in the first step of glutathione synthesis. |
PC-62918 |
PSB-12431
|
PSB-12431 is an α,β-Methylene-ADP (AOPCP) derivative, potent, selective ecto-5′-Nucleotidase (eN, CD73) inhibitor with Ki of 9.2 nM for rat recombinant eN. |
PC-62917 |
PSB-12553
|
PSB-12553 is an α,β-Methylene-ADP (AOPCP) derivative, potent, selective ecto-5′-Nucleotidase (eN, CD73) inhibitor with Ki of 9.5 nM for rat recombinant eN. |
PC-62916 |
PSB-12379 disodium
|
PSB-12379 is an α,β-Methylene-ADP (AOPCP) derivative, potent, selective ecto-5′-Nucleotidase (eN, CD73) inhibitor with Ki of 9.03/2.21 nM for rat/human recombinant eN. |
PC-62874 |
ARN 726
|
ARN726 is a potent, selective, orally bioavailable N-acylethanolamine acid amidase (NAAA) inhibitor with IC50 of 63 nM (r-NAAA) and 27 nM (h-NAAA). |
PC-62873 |
ARN 077
|
ARN077 is the first potent, selective N-acylethanolamine acid amidase (NAAA) inhibitor with IC50 of 7 nM on both rat NAAA and human NAAA. |